The Psych Behind Psychedelics: Exploring Hallucinogen Use as a Marker for Untreated Mental Health Disorders

HPR

Health Psychology Research

TBA2420-8124

Health Psychology Research

10.52965/001c.127794

General

The Psych Behind Psychedelics: Exploring Hallucinogen Use as a Marker for Untreated Mental Health Disordershttps://healthpr.org/journal/HPR/13/1/10.52965/001c.127794AhmedLiyana,KondaSanjana,GantiLatha

2025

131

2025-01-06

Objective Are individuals who use hallucinogens self-medicating their mental illness and are they more likely to abuse other illegal substances?   Design, setting, participants Data from the National Survey on Drug Use and Health (NSDUH), collected by the Substance Abuse and Mental Health Services Administration (SAMHSA) database was queried for correlations with hallucinogen use. Using age group as a control variable, different variables were run through a crosstab in order to find significant data pointing to the implications of hallucinogen use.   Results The data from the crosstab analysis showed three key findings about hallucinogen use: Those with mental illness or substance abuse issues were substantially more likely to use hallucinogens, the hallucinogen use greatly increased with the pandemic along with further mental health issues, and those who used hallucinogens were more significantly likely to abuse other illegal substances, primarily in a younger population.   Conclusion The positive correlation between mental health issues and hallucinogen use emphasizes the need for better mental health services, especially after the COVID-19 pandemic. The positive correlation between hallucinogen use and other drug use indicates the widespread drug abuse problem, especially within a younger population in which drugs pose a larger neurological threat.

1.Nichols DE. Hallucinogens. Pharmacology & Therapeutics. 2004;101(2):131-181. doi:10.1016/j.pharmthera.2003.11.002 Google Scholar 2.Abraham HD, Aldridge AM. Adverse consequences of lysergic acid diethylamide. Addiction. 1993;88(10):1327-1334. doi:10.1111/j.1360-0443.1993.tb02018.x Google Scholar 3.Nichols DE. Psychedelics. Pharmacological Reviews. 2016;68(2):264-355. doi:10.1124/pr.115.011478 Google Scholar 4.Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics. 2019;197:83-102. doi:10.1016/j.pharmthera.2018.11.010 Google Scholar 5.Miller L. Hallucinogen addiction: Types & effects of mind-altering drugs. American Addiction Centers. May 17, 2023. https://americanaddictioncenters.org/hallucinogens 6.Hallucinogen abuse signs & symptoms. Longleaf Hospital. May 24, 2018. https://www.longleafhospital.com/addiction/hallucinogen/signs-symptoms-effects/ 7.Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE. Psychedelics and Other Psychoplastogens for Treating Mental Illness. Frontiers in Psychiatry. 2021;12. doi:10.3389/fpsyt.2021.727117 Google Scholar 8.Dos Santos RG, Bouso JC, Rocha JM, Rossi GN, Hallak JE. The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges. Risk Management and Healthcare Policy. 2021;14:901-910. doi:10.2147/rmhp.s300656 Google Scholar 9.Tupper KW, Wood E, Yensen R, Johnson MW. Psychedelic medicine: a re-emerging therapeutic paradigm. Canadian Medical Association Journal. 2015;187(14):1054-1059. doi:10.1503/cmaj.141124 Google Scholar 10.Shiraly R, Jazayeri SA, Seifaei A, Jeihooni AK, Griffiths MD. Suicidal thoughts and behaviors among untreated illicit substance users: a population-based study. Harm Reduction Journal. 2024;21(1). doi:10.1186/s12954-024-01015-9 Google Scholar 11.National Survey on Drug Use and health. SAMHSA.gov. https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health 12.Kopra EI, Ferris JA, Winstock AR, Kuypers KP, Young AH, Rucker JJ. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020. Journal of Psychopharmacology. 2023;37(7):733-748. doi:10.1177/02698811231158245 Google Scholar 13.Hadar-Shoval D, Alon-Tirosh M, Asraf K, Tannous-Haddad L, Tzischinsky O. Lifestyle Changes, Emotional Eating, Gender, and Stress during COVID-19 Lockdown. Nutrients. 2022;14(18):3868. doi:10.3390/nu14183868 Google Scholar 14.World Health Organization. Mental health and covid-19. World Health Organization. https://www.who.int/teams/mental-health-and-substance-use/mental-health-and-covid-19 15.U.S. Department of Health and Human Services. Covid-19 and mental health. National Institute of Mental Health. https://www.nimh.nih.gov/health/topics/covid-19-and-mental-health 16.Winters KC, Arria A. Adolescent Brain Development and Drugs. The prevention researcher. 2011;18(2):21-24. Google Scholar